A polymerase chain reaction (PCR)-based assay was developed for the detection ofPneumocystis carinii DNA in induced sputum and bronchoscopic alveolar lavage samples. The In the present study, the PCR assay was tested on 42 sputum samples as well as 43 BAL samples, all of which were previously tested by IFL. The detection of P. carinii DNA in respiratory samples by PCR was compared with the results of detection by IFL and the clinical symptoms of the patients. The influence of chemoprophylaxis against P. carinii on the ability to detect the organism was also determined by comparing the results of IFL and PCR.
Pneumocystis carinii is a eucaryotic opportunistic pathogen which causes serious pneumonia (P. carinii pneumonia [PCP] ) in immunosuppressed patients. PCP is the initial disease manifestation in 60% of patients with AIDS and is estimated to ultimately occur in up to 80% of patients with AIDS (1) . The infection also occurs in patients receiving immunosuppressive therapy.
Laboratory diagnosis of PCP is dependent on microscopic demonstration of the organism by using conventional cytochemical (i.e., toluidine blue 0, Grocott's methenamine silver, or Giemsa) staining. Increased specificity and sensitivity are achieved by immunocytochemical staining (immunofluorescence [IFL] ) with monoclonal antibodies (3, 11) . Improvement in sensitivity cannot be obtained by in vitro propagation (1) . However, the development of the polymerase chain reaction (PCR) (12) , a gene amplification procedure by which any specific DNA fragment can be exponentially accumulated in vitro, has made it possible to detect very small numbers of pathogens in clinical specimens. Wakefield et al. (16) have presented clinical applications of a PCR assay based on sequences coding for mitochondrial rRNA of P. carinii derived from infected rats. In both sputum (14) and bronchoalveolar lavage (BAL) samples (15) , PCR offered a more sensitive technique than cytochemical staining (Grocott's methamine silver staining) for the diagnosis of PCP.
In the present study we established a diagnostic PCR assay based on the amplification of the thymidylate synthase (TS) gene of P. carinii derived from infected rats. The amplified sequence of 403 bp was identical to the sequence of the region previously cloned and sequenced by Edman et al. (2) , who used degenerated oligonucleotide primers based on * Corresponding author.
conserved regions of different TS amino acid sequences in order to isolate this region of the P. carinii genome.
In the present study, the PCR assay was tested on 42 sputum samples as well as 43 BAL samples, all of which were previously tested by IFL. The detection of P. carinii DNA in respiratory samples by PCR was compared with the results of detection by IFL and the clinical symptoms of the patients. The influence of chemoprophylaxis against P. carinii on the ability to detect the organism was also determined by comparing the results of IFL and PCR.
MATERIALS AND METHODS
Control organisms. P. carinii isolated from infected human lung tissue (autopsy material) was used for optimizing the PCR protocol and as an amplification control in all experiments. The organisms were prepared by an enzyme digestion method described previously (5) but that was modified by omitting incubation with DNase.
To determine the specificity of the assay, fungal and bacterial species (Candida tropicalis, Candida glabrata, Candida albicans serotype A, C. albicans serotype B, Candida parapsilosis, Cryptococcus neoformans, Aspergillus fumigatus, Mycobacterium tuberculosis) colonizing different parts of the human respiratory tract were used. The fungal species and M. tuberculosis were obtained as in vitro strains, whereas the human bacterial flora was collected from the upper respiratory tracts of 20 healthy subjects. The bacteria were isolated on blood agar, and the total DNA was extracted as a pool (see below).
Clinical samples. Sputum and BAL samples selected for analysis by PCR were obtained from 1987 to 1991 (Table 1) and were tested for the presence of P. carinii by IFL (see below). Most of the sputum samples were obtained from patients with respiratory symptoms, but six of the sputum samples were from asymptomatic human immunodeficiency virus (HIV)-infected patients (participating in a study on pentamidine prophylaxis against P. carinii). Thirty-four sputum samples were acquired from patients with HIV infection (samples Al to A17 and Bi to B17 in Table 1 ) and eight were from non-HIV-infected patients (samples A18 to A21 and B18 to B21 in Table 1 ).
Five patients had received treatment for PCP between 2 and 14 days before the sampling day (see Table 4 ). Four of the patients were infected with HIV, and the fifth patient suffered from chronic lymphatic leukemia. Six HIV-infected patients received primary prophylactic nebulized pentamidine against P. carinii (no previous episode of PCP), and eight patients received the same drug as secondary prophylaxis (previous episode of PCP).
The BAL samples were from non-HIV-infected patients with or without immunosuppression (samples Cl to C43 in Table 1 ). The PCR products of the clinical samples were analyzed by agarose gel electrophoresis (AGE) and then by slot blot hybridization (see below). Some PCR products from clinical samples were also analyzed by Southern blotting.
Sample preparation. All sputum and BAL samples containing mucous material were liquefied with 6.3 mM dithiothreitol for at least 5 min at room temperature. Samples were then treated with a 25% final concentration of ethanol for inactivation of HIV, pelleted by centrifugation at 2,000 x g for 5 min, and stored at 4°C. Prior to analysis by PCR, the samples were washed once with 0.14 M phosphate-buffered saline (pH 7.4), centrifuged at 2,000 x g for 5 min, and resuspended in the same buffer. A volume of 100 Rl was used for DNA isolation. In order to break the cyst wall of the parasite, the samples were treated with the following protocol, which was based on one described by Holm et al. (6) sucrose, 0.1 M sodium citrate, and 1 mM Na2EDTA (pH 8). After centrifugation at 3,000 x g for 5 min, the cell pellets were resuspended in a lysis buffer containing 100 mM Tris-HCl (pH 8), 75 mM NaCl, and 25 mM EDTA (pH 8), freeze-thawed once, and digested with 200 p,g of fresh proteinase K per ml in 0.5% sodium dodecyl sulfate (SDS) for 60 min at 55°C. The samples were then extracted with saturated phenol by the following triple procedure: extraction with an equal volume of phenol, then with a 25:24:1 mixture of phenol-chloroform-isoamyl alcohol, and finally with a 24:1 mixture of chloroform-isoamyl alcohol. The DNA in the final water phase was precipitated with 2 volumes of ethanol and was resuspended in TE buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA). Five micrograms of tRNA per ml was added as a carrier in the extraction and precipitation procedure. DNAs from the P. cannii-infected human lung tissue and the fungal cultures were also isolated by this protocol. The DNA extraction from human pooled bacteria on blood agar and M. tuberculosis strain culture was preceded with lysozyme and pronase digestion as described previously (4) .
Detection of P. carinii by IFL. IFL was performed with a mouse monoclonal antibody to P. carinii (9) and fluorescein isothiocyanate-conjugated sheep anti-mouse immunoglobulin as described by Elvin et al. (3) .
Amplification. The two oligonucleotide primers PC1 and PC2 as well as the internal probe ( Fig. 1) were synthesized by using a Gene Assembler (Pharmacia, Uppsala, Sweden) and were purified according to the manufacturer's protocol. Primer PC1 corresponds to nucleotides 379 to 396 and primer PC2 corresponds to nucleotides 763 to 781 in the published sequence of the TS gene of P. carinii derived from infected rats (2) . The amplification product consisted of a 403-bp DNA fragment, including two intervening sequences of 45 and 55 bp, respectively (Fig. 1) .
The amplification reactions were performed as described by Saiki et al. (12 All experiments were performed in parallel with P. carinji DNA extracted from the human lung homogenate as a positive control and with water as a negative control. To avoid contamination, the DNA preparation of the samples, the addition of PCR reagents, and the detection procedures were performed in physically separated areas with different sets of micropipettes. Ten microliters of the PCR product was analyzed for the presence of the 403-bp PCR product by AGE on 3% Nusieve-1% agarose (FMC Bioproducts, Rockland, Maine).
Detection level. Because the DNA preparation from the human P. cannii-infected lung homogenate contained both human and P. cannii DNAs, we estimated the detection level of the PCR assay by using the 403-bp PCR fragment as a target for reamplification. The DNA concentration was determined by measuring the optical density at 260 nm, and the fragment was diluted 10-fold in 25 ,ug of human DNA per ml. The human DNA was extracted from clinical sputum samples, which were negative for P. carinii by IFL and PCR. This was done in order to mimic the biological conditions in clinical sputum and BAL samples. The reamplified PCR product was then detected by AGE and slot blot hybridization (see above and below).
Analysis of PCR products by hybridization. PCR products (10 p,l) were either transferred from agarose gels to nitrocellulose membranes (Schleicher & Schuell, GmbH, Dassel, Germany) by vacuum blotting (Hybaid) or heat denatured and applied to Hybond N membranes (Amersham, Bucks, United Kingdom) with a slot blot apparatus (Millipore, Bedford, Mass.). Both types of membranes were baked for 2 h at 80°C under vacuum and were hybridized to a 32P-labeled probe (Fig. 1, positions 514 to 541) with a specific activity of at least 108 cpm/lpg of DNA. The hybridization conditions were as follows: 43°C for 2 h in 6x SSC (0.9 M NaCl plus 0.09 M sodium citrate) containing 3x Denhardt solution (0.06% Ficoll 400, 0.06% polyvinylpyrrolidone, 0.06% bovine serum albumin fraction V), 0.5% SDS, 0.1% tetrasodium pyrophosphate decahydrate, and 0.2 mg of sonicated salmon sperm DNA (Sigma) per ml. Filters were washed three times for 5 min each time with 6x SSC-0.1% SDS-0.1% tetrasodium pyrophosphate decahydrate at 20°C and then three times for 5 min each time in the same solution at 43°C; thereafter, the filters were exposed to RPN-6 film (Amersham) at -70°C.
RESULTS
Specificity. We applied the PCR technique by using the primer pair PC1 and PC2 for amplification of DNA from P. carinii-infected human lung tissue and clinical respiratory samples. The size of the amplified product as analyzed by AGE (Fig. 2) was 403 bp, as predicted from the TS gene sequence (Fig. 1) . When the primer pair was tested for specificity on DNA preparations from 10 different microorganisms, no signs of amplified DNA could be seen in the agarose gels (Fig. 2) . Moreover, the P. carinii probe (Fig. 1) used to confirm the presence of P. carinii was hybridized to the microbial DNA preparations, and no positive reaction could be seen by autoradiography after Southern blot analysis (Fig. 2 ). carinii-specific probe. Detection level. We were able to detect 10 copies of the target DNA, or 10-18 g of P. carinii-specific DNA, in a sample volume of 10 ,ul by slot blot hybridization (Fig. 32 . The PCR detection level for AGE was 10 times lower g).
Detection of the 403-bp sequence in clinical samples. The results of the PCR assay detected by AGE and DNA hybridization (Fig. 4 ) for all clinical material tested retrospectively in comparison with the results of IFL are given in (2) . It is therefore likely that the corresponding gene is conserved in various isolates of P. carinii, but it may also be similar to sequences in other organisms. The specificity of the intervening sequences of the rat P. carinii TS gene (2) made it possible to design a confirmative oligonucleotide probe specific only to the PCR product of P. carinii. No falsepositive PCR product visible as a band in AGE could be detected after amplification of DNA from fungal and bacterial organisms by using primer pair PC1 and PC2 (Fig. 1) . The specificity of the probe is indicated by the positive reaction with amplified P. caninii DNA and the negative reactions with DNAs from the control microorganisms when analyzed by the Southern blotting technique (Fig. 2) .
Since diagnostic confirmation of P. carinii infection cannot be achieved by in vitro propagation, IFL serves as the reference method for detection of the organism. The nine PCR-positive sputum samples which were IFL negative are likely to be true positives because only two samples were from patients without verified PCP (Table 3) . Amplified DNA in these latter two sputum samples was detected by weak signals by DNA hybridization, whereas the hybridization signal was weak in only one of the four sputum samples from patients with verified PCP (data not shown).
Although there was a limited amount of sputum samples that could be analyzed and two patients received a prophylactic regimen (trimethoprim and pyrimethamine, respectively, which are no longer considered adequate prophylaxis; see Table 4 ), the PCR assay seems to be even more advantageous than IFL for detection of P. carinii in sputum samples from HIV-infected patients receiving prophylactic treatment against P. carindi. Detection rates were similar by the two methods for sputum samples from treated and untreated patients. Our results are consistent with the indication that induced sputum samples examined for P. carinii by IFL have a lower diagnostic yield for HIV-infected patients who have received previous aerosolized pentamidine prophylaxis than for patients without anti-P. carindi chemoprophylaxis (7, 8) .
By the PCR assay described here, we also detected P.
carinii DNA in 5 (Cl to C2, C13, C21, and C24; al. (14, 15) . However, they compared the PCR method with silver staining, which is less sensitive than our reference method (IFL) for detection ofP. carinii (3, 11) . We conclude that the application of PCR described here is specific and more sensitive than IFL for detection of P. caninii.
In order for P. cainni PCR to become a generally used assay in clinical laboratories, the DNA extraction, detection, and confirmation procedures in the current protocol need to be simplified. We are testing new DNA extraction methods, but so far none have shown results as good as those obtained by standard phenol extraction. For confirmation of the specificity of an amplified DNA fragment, restriction analysis is a simple and less costly alternative to time-consuming DNA hybridization. Another approach, which is easy to perform and standardize, is the reversed dot blot technique (13) , in which the PCR product is nonisotopically labeled and hybridized to an immobilized probe.
